

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-146 (Canceled)

Claim 147 (Currently amended) A method of obtaining a composition which comprises determining whether a chemical compound binds to a human Y4 receptor expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to the receptor, admixing the compound with a carrier; wherein the human Y4 receptor (1) has an amino acid sequence identical to the amino acid sequence shown in Figure 1 (SEQ ID NO: 2), or (2) is encoded by a nucleic acid sequence identical to the receptor-encoding nucleic acid sequence contained in plasmid pcEXV-Y4 (ATCC Accession No. 75631).

Claim 148 (Currently Amended) A method of obtaining a composition which comprises screening compounds to identify compounds which interact with, and specifically bind to a human Y4 receptor expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound interacts with and specifically binds to the receptor, admixing the compound with a carrier; wherein the human Y4 receptor (1) has an amino acid sequence identical to the amino acid sequence shown in Figure 1 (SEQ ID

Jonathan A. Bard, et al.
Serial No.: 09/430,775
Filed: October 29, 1999
Page 10

NO: 2), or (2) is encoded by a nucleic acid sequence
identical to the receptor-encoding nucleic acid
sequence contained in plasmid pcEXV-Y4 (ATCC
Accession No. 75631).

Claims 149-152 (Canceled)

Claim 153 (Currently Amended) The method of any of claims 147
[,] or or 148, ~~149 or 150~~, wherein the composition
is a pharmaceutical composition and the carrier is a
pharmaceutically acceptable carrier.